Listenly

What percentage of global key starting materials in pharmaceutical manufacturing originate from China?

Answered at 5:44 in Why Procurement Can Make or Break a Drug Company · Executive Edge Podcast

— questions searchable right now

What percentage of global key starting materials in pharmaceutical manufacturing originate from China?

About 37% of the chemicals used as key starting materials are globally sourced out of China and may then be shipped to another CDMO that makes the active pharmaceutical ingredient, which could be in Europe, the U.S., or Japan.

Dave Stowe on Executive Edge PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

About 37% of the chemicals used as key starting materials are globally sourced out of China and may then be shipped to another CDMO that makes the active pharmaceutical ingredient, which could be in Europe, the U.S., or Japan.

Dave Stowe, Founder and Managing Partner at Adventus · Why Procurement Can Make or Break a Drug Company · Executive Edge Podcast · answer at 5:44

Key takeaways

  • About 37% of the chemicals used as key starting materials are globally sourced out of China and may then be shipped to another CDMO that makes the active pharmaceutical ingredient, which could be in Europe, the U.S., or Japan.

Quote to remember

“There's always this challenge, right? It's a game of capacity management. You know, you can imagine you're buying capacity at the CDMO. They could sell it to somebody else.”

— Dave Stowe

The full answer · about 1 min

About 37% of the chemicals used as key starting materials are globally sourced out of China and may then be shipped to another CDMO that makes the active pharmaceutical ingredient, which could be in Europe, the U.S., or Japan.

Key facts

  • 37% of global chemicals in pharmaceutical manufacturing originate from China
  • CDMO biologics manufacturing forecasted at 8 to 12% compound annual growth rate over seven years
  • Drug development timeline: 2 to 5 to 10 years from preclinical through full production
  • Radioisotope half-life example: 5-day half-life requiring overnight shipping from Indiana to patient administration
  • Injectable syringe viscosity requirement: under 5 to 10 milliliters

People, companies and topics mentioned

AdventusCDMO (Contract Development Manufacturing Organization)FDA (Food and Drug Administration)PwCOliver WymanHorizon TherapeuticsPurdue PharmaKSM (Key Starting Materials)

More answers from this episode

 ·  All answers from Executive Edge Podcast →
—
—
0:00
0:00